Início › Doença de Crohn › Illinois
Ensaios clínicos de Doença de Crohn em Illinois
18 estudos para Doença de Crohn estão buscando participantes em locais em Illinois.
Cidades em Illinois
Texto oficial do estudo (Inglês)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Chicago Medical Center ( Site 5066), Chicago
- Endeavor Health ( Site 5018), Evanston
- GI ALLIANCE - GURNEE ( Site 5003), Gurnee
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Midwest Digestive Health & Nutrition /ID# 285250, Des Plaines
- Gi Alliance - Glenview /ID# 283932, Glenview
- Illinois Gastroenterology Group /ID# 283933, Gurnee
- e mais 1
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Yapp, Rockford M.D. (Private Practice), Downers Grove
- GI Alliance - Glenview, Glenview
- Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
- e mais 3
RecrutandoFase 4
Idades de 18 a 80 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Chicago Medical Center /ID# 267400, Chicago
- OSF St. Francis Medical Center /ID# 266973, Peoria
- Springfield Clinic Main Campus /ID# 267434, Springfield
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Rush University Medical Center, Chicago
RecrutandoFase 3
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Rush University Medical Center-Site Number: 8400015, Chicago
- Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
- GI Alliance - Glenview-Site Number: 8400068, Glenview
- e mais 1
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184944A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Rush University Medical Center, Chicago
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Rush University Medical Center, Chicago
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Chicago Medicine, Chicago
RecrutandoFase 4
Idades de 18 a 70 · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Chicago Medicine, Chicago
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- OSF St. Francis Medical Center /ID# 262192, Peoria
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
RecrutandoFase 3
Idades 2 e acima · Todos os sexos · Atualizado em 7 de mai. de 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Northwestern University, Evanston
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 27 de abr. de 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 12 de mar. de 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Northwestern, Chicago
- University of Chicago, Chicago
RecrutandoFase 1/2
Idades de 18 a 65 · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT06721962Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.